세계의 폼 드레싱 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Foam Dressing Market Size, Share & Trends Analysis Report By Type (Adhesive Foam Dressing, Non-adhesive Foam Dressing), By Application (Chronic Wounds, Acute Wounds), By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

폼 드레싱 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 폼 드레싱 세계 시장 규모는 2024년부터 2030년까지 4.73%의 연평균 복합 성장률(CAGR)로 확대되어 2030년에는 25억 2,000만 달러에 달할 것으로 예상됩니다.

시장 성장을 가속하는 주요 요인으로는 수술 건수 증가, 급속한 고령화, 당뇨병 환자 증가 등을 들 수 있습니다. 예를 들어, 세계경제포럼에 따르면 현재 일본의 65세 이상 인구는 전체 인구의 25%에 달할 전망입니다. 이 수치는 2060년에는 40%까지 증가할 것으로 예상되고 있습니다. 노인들은 상처를 입기 쉽기 때문에 폼 드레싱 시장은 예측 기간 동안 성장할 것으로 예상됩니다.

비만 및 과체중 인구 증가도 시장을 활성화시키는 요인 중 하나입니다. 예를 들어, Sage Journals &Indian Academy of Neurosciences의 기사에 따르면 2021년 인도의 비만 인구는 1억 3,500만 명으로 추산됩니다. 마찬가지로, Obesity Evidence Hub에 따르면 호주인의 3분의 2, 즉 35.6%가 과체중이고 31.3%가 비만이 될 것으로 예상됩니다. 이러한 상황은 비만 치료 및 기타 관련 수술에 대한 수요를 증가시켜 예상 기간 동안 시장 성장을 가속할 것으로 예상됩니다.

또한, 코로나19 백신의 출시와 감금 규제 완화로 인해 향후 몇 년동안 이 산업은 성장할 것으로 예상됩니다. 연기되었던 많은 선택적 수술이 시행될 것으로 예상됩니다. 또한, 많은 상위 제조업체들이 신규 출시, 제휴, 지리적 확장과 같은 전략적 활동을 통해 예측 기간 동안 폼 드레싱 제품에 대한 수요 증가로 이익을 얻을 수 있는 전략적 활동을 하고 있습니다. 예를 들어, 2022년 2월 Medline Industries는 폼 드레싱 Optifoam Gentle EX Foam Dressing의 새로운 버전 출시를 발표했습니다. 이 제품은 욕창 예방 프로토콜에 사용될 때마다 압력을 변위하도록 특별히 설계되었습니다. 이와 같이 다른 시장 진출기업들의 유사한 노력은 팬데믹 이후 시장 성장을 가속할 것으로 예상됩니다.

폼 드레싱 시장 보고서 하이라이트

• 유형별로는 점착성 폼 드레싱이 2023년 56.59%의 매출 점유율을 차지하며 시장을 장악했습니다.
• 용도별로는 만성 상처 치료제 부문이 2023년 59.83%의 매출 점유율을 차지하며 시장을 주도했습니다.
• 최종 용도별로는 입원 환자의 수술 부위 감염 증가로 인해 병원 부문이 시장을 주도하고 있습니다. 반면, 재택치료 부문은 예측 기간 동안 가장 빠른 CAGR을 나타낼 것으로 예상됩니다.
• 북미는 당뇨병 환자 증가, 비만 인구 증가, 기술 발전으로 인해 2023년 45.46%의 가장 높은 매출 점유율을 차지하며 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 폼 드레싱 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 시장 분석 툴
  • Porter의 Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 폼 드레싱 : 유형 추정·동향 분석

• 폼 드레싱 시장 : 유형 변동 분석
  • 접착
  • 비접착

제5장 폼 드레싱 : 최종 용도 추정·동향 분석

• 폼 드레싱 시장 : 최종 용도 변동 분석

제6장 폼 드레싱 : 용도 추정·동향 분석

• 폼 드레싱 시장 : 용도 변동 분석
  • 급성 창상
  • 만성 창상

제7장 폼 드레싱 시장 : 지역 추정·동향 분석

• 세계의 지역 시장 현황
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • 3M
  • COLOPLAST CORP
  • MEDLINE INDUSTRIES
  • SMITH &NEPHEW
  • CARDINAL HEALTH
  • CONVATEC GROUP PLC
  • DERMA SCIENCES(INTEGRA LIFESCIENCES)
  • ETHICON(JOHNSON &JOHNSON)
  • MCKESSON CORPORATION
  • MOLNLYCKE HEALTH CARE AB

LSH

영문 목차

영문목차

Foam Dressing Market Growth & Trends:

The global foam dressing market size is expected to reach USD 2.52 billion by 2030, expanding at a CAGR of 4.73% from 2024 to 2030, according to a new report by Grand View Research, Inc. A few of the key drivers propelling the market growth include an increase in surgical cases, a rapidly aging population, and an increase in the number of diabetes patients. For instance, according to the World Economic Forum, the current population of Japanese people above 65 years of age is 25% of the total population. This number is further expected to rise to 40% by 2060. Older people are more likely to sustain wounds, thus, the market for foam dressing is expected to grow throughout the forecast period.

An increase in the number of obese/overweight people is another fueling factor of the market. For instance, according to an article by Sage Journals & Indian Academy of Neurosciences, 2021, the number of obese people in India is estimated to be 135 million. Similarly, as per the Obesity Evidence Hub, two-thirds of the Australian people, i.e., 35.6% are overweight, whereas, 31.3% are expected to be obese. These situations are anticipated to raise demand for bariatric treatments and other related surgeries, driving the growth of the market over the anticipated time frame.

Additionally, the industry is anticipated to grow in the upcoming years with the launch of the COVID-19 vaccine and the relaxation of lockdown restrictions. It is anticipated that many elective procedures will be performed that were delayed. Moreover, many top producers are engaged in strategic activities including new launches, partnerships, and geographic expansion that could enable them to profit from the rising demand for foam dressing products during the projection period. For instance, in February 2022, Medline Industries announced the launch of a new version of its foam dressing Optifoam Gentle EX Foam Dressing. This is specially designed to displace the pressure whenever used with a pressure injury prevention protocol. Thus, similar initiatives by other market players are anticipated to boost market growth during the post-pandemic time.

Foam Dressing Market Report Highlights:

• Based on type, the adhesive foam dressing segment dominated the market and accounted for a revenue share of 56.59% in 2023, owing to an increase in the number of high exudate wound patients
• Based on application, the chronic wound application segment accounted for a revenue share of 59.83% in 2023 and is leading the market
• Based on end-use, the hospital segment dominated the market, due to an increase in surgical site infections among hospital patients. On the other hand, during the projected period, the home healthcare segment is anticipated to witness the fastest CAGR over the forecast period
• North America dominated the market and accounted for the highest revenue share of 45.46% in 2023 owing to the increasing number of diabetic patients, rise in the number of obese population, and technological advancements

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Application
  • 1.1.3. End-use
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Foam Dressing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing number of people suffering from chronic wounds
    • 3.2.1.2. Increasing number of traumatic accidents
    • 3.2.1.3. Increasing global geriatric population
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Availability of various substitute
    • 3.2.2.2. Stringent regulations for foam dressings
• 3.3. Organoids & Spheroids Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Foam Dressing: Type Estimates & Trend Analysis

• 4.1. Foam Dressing Market: Type Movement Analysis
  • 4.1.1. Adhesive Foam Dressing
    • 4.1.1.1. Adhesive foam market estimates and forecast, 2018 - 2030
  • 4.1.2. Non-adhesive Foam Dressing
    • 4.1.2.1. Non-adhesive foam dressing market estimates and forecast, 2018 - 2030

Chapter 5. Foam Dressing: End-Use Estimates & Trend Analysis

• 5.1. Foam Dressing Market: End-Use Movement Analysis
  • 5.1.1. Hospitals
    • 5.1.1.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
  • 5.1.2. Specialty clinics
    • 5.1.2.1. Specialty clinics Institutes market estimates and forecast 2018 to 2030 (USD Million)
  • 5.1.3. Home Healthcare
    • 5.1.3.1. Home healthcare market estimates and forecast 2018 to 2030 (USD Million)
  • 5.1.4. Others
    • 5.1.4.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Foam Dressing: Application Estimates & Trend Analysis

• 6.1. Foam Dressing Market: Application Movement Analysis
  • 6.1.1. Acute Wounds
    • 6.1.1.1. Acute wounds market estimates and forecast 2018 to 2030 (USD Million)
    • 6.1.1.2. Surgical & Traumatic Wounds
    • 6.1.1.2.1. Surgical & traumatic wounds market estimates and forecast 2018 to 2030 (USD Million)
    • 6.1.1.3. Burns
    • 6.1.1.3.1. Burns market estimates and forecast 2018 to 2030 (USD Million)
  • 6.1.2. Chronic Wounds
    • 6.1.2.1. Chronic wounds market estimates and forecast 2018 to 2030 (USD Million)
    • 6.1.2.2. Diabetic Foot Ulcers
    • 6.1.2.2.1. Diabetic foot ulcers market estimates and forecast 2018 to 2030 (USD Million)
    • 6.1.2.3. Pressure Ulcers
    • 6.1.2.3.1. Pressure ulcers market estimates and forecast 2018 to 2030 (USD Million)
    • 6.1.2.4. Venous Leg Ulcers
    • 6.1.2.4.1. Venous leg ulcers market estimates and forecast 2018 to 2030 (USD Million)
    • 6.1.2.5. Other Chronic Wounds
    • 6.1.2.5.1. Other chronic wounds market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Foam Dressing Market: Regional Estimates & Trend Analysis

• 7.1. Global Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Target Disease Prevalence
    • 7.2.2.3. Competitive Scenario
    • 7.2.2.4. U.S. Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Canada Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.3. Europe
  • 7.3.1. Europe Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. UK Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Germany Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. France Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Italy Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Spain Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Denmark Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Sweden Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Norway Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.2. China
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. China Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.3. Japan
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Japan Market estimates and forecast, 2018 - 2030 (Volume, Thousand)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. India Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.5. Australia
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Australia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.6. Thailand
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Thailand Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.7. South Korea
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. South Korea Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.5. Latin America
  • 7.5.1. Latin America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. Brazil Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.3. Mexico
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Mexico Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.4. Argentina
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Argentina Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.6. MEA
  • 7.6.1. MEA Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Saudi Arabia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.6.3. South Africa
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. South Africa Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. UAE Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Kuwait Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key Company Market Share Analysis, 2022
  • 8.3.4. 3M
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. COLOPLAST CORP
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. MEDLINE INDUSTRIES
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. SMITH & NEPHEW
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. CARDINAL HEALTH
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. CONVATEC GROUP PLC
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. DERMA SCIENCES (INTEGRA LIFESCIENCES)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. ETHICON (JOHNSON & JOHNSON)
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. MCKESSON CORPORATION
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. MOLNLYCKE HEALTH CARE AB
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives

관련자료